Biogen pushing tau drug forward despite Alzheimer’s study failure

Biogen Advances Tau Drug Despite Phase 2 Primary Endpoint Miss

Biogen announced "unprecedented and compelling" results from its Phase 2 "Celia" study of BIIB080 (diranersen) in early Alzheimer’s disease, despite the trial failing its primary endpoint of finding a dose response. The experimental medicine demonstrated a slowing of cognitive decline across all doses, with the lowest dose showing particular efficacy, and successfully reduced levels of the tau protein. Biogen plans to advance the drug to late-stage testing, with full data to be presented at the Alzheimer’s Association International Conference in July.

• The Phase 2 "Celia" study for BIIB080, while not meeting its primary endpoint of dose response, showed promising evidence of slowing cognitive decline in early Alzheimer's patients. Researchers observed this benefit across all tested doses, with the lowest 60 mg dose administered every 24 weeks demonstrating a notable effect, suggesting potential clinical utility despite the unexpected dose-response profile.
• BIIB080 successfully reduced levels of tau, a protein implicated in Alzheimer's pathology, reinforcing its mechanism as an antisense oligonucleotide. This genetic medicine is designed to block the cellular instructions that lead to excessive tau production, thereby mitigating its toxic effects. This biomarker data is a key factor driving Biogen's decision to advance the program.
• Despite the mixed results and initial investor skepticism (Biogen shares fell approximately 5% after an initial premarket bump), Biogen expressed strong confidence in the data, particularly the biomarker and efficacy signals, and intends to move BIIB080 into late-stage testing. Detailed findings are anticipated at the upcoming Alzheimer’s Association International Conference in July, which will provide more clarity on the drug's potential.

Diranersen's Novel Approach to Targeting Tau in Alzheimer's

Alzheimer's disease is driven by complex interactions between genetic predisposition and pathological protein accumulation. Four genes have been definitively linked to familial cases through genetic screening: amyloid precursor protein (APP), presenilin 1 (PSEN1), presenilin 2 (PSEN2), and apolipoprotein E (APOE). Mutations in APP, PSEN1, and PSEN2 cause enhanced production of β-amyloid found in neuritic plaques, while the APOE ε4 allele does not increase amyloid production but enhances its deposition. However, these identified genes account for only approximately 10% of total Alzheimer's cases, indicating that significant genetic factors remain undiscovered. Additional susceptibility loci include ABCA7, CR1, MS4A6A, CD2AP, TREM2, and genes encoding inflammatory mediators such as interleukin-6 and alpha-2-macroglobulin, with specific deleterious single nucleotide polymorphisms identified across these loci.

The amyloid cascade represents a central pathogenic mechanism, where compelling genetic and neurobiological evidence suggests that amyloid accumulation in the brain initiates and drives early-stage disease progression. Formation of cytotoxic oligomers consisting of Aβ peptide, resulting from specific proteolytic processing of APP, is widely accepted as a key triggering event in disease development. This process is intimately connected to tau pathology through cytoskeletal changes and formation of paired helical filaments, which are common to both neuritic plaques and neurofibrillary tangles. The ceramide pathway has emerged as a potentially central mechanism, with multiple lines of evidence indicating that various seemingly unrelated risk factors—including genetic mutations, tumor necrosis factor-α, saturated fatty acids, and cortisol—converge on ceramide production, which subsequently disrupts mitochondrial function and promotes both amyloid production and tau hyperphosphorylation.

Inflammatory and oxidative stress mechanisms provide additional pathogenic complexity, with genetic analysis revealing that glial cell inflammatory responses significantly modify disease pathophysiology. The disease involves multiple converging pathogenic events including genetic factors, accumulation of misfolded proteins, ubiquitin-proteasome system dysfunction, excitotoxic reactions, mitochondrial injury, synaptic failure, and altered metal homeostasis. Environmental factors and epigenetic phenomena further contribute to pathology and phenotypic expression, with the aging process exerting deleterious effects in conjunction with genetic factors, cerebrovascular deterioration, and nutritional influences. This multifactorial nature, combined with the complex inheritance patterns observed, underscores why Alzheimer's disease remains a heterogeneous neurodegenerative disorder driven by pathological protein depositions across multiple cellular and molecular pathways.

Unpacking the Phase 2 Celia Study's Efficacy and Safety Data

Recent clinical studies in Alzheimer's disease have generated important efficacy and safety data across multiple therapeutic modalities. The following studies represent key developments in the field, spanning from anti-amyloid antibodies to novel interventions like acupuncture and stem cell therapy.

• Clarity AD Trial (Lecanemab): This monoclonal antibody targeting amyloid-beta achieved 81% of patients reaching amyloid-negative PET scans and demonstrated a 27% reduction in cognitive decline on the ADCOMS scale, though amyloid-related imaging abnormalities (ARIA) required systematic monitoring for safety.

• Donanemab Trial: The anti-amyloid monoclonal antibody showed promising efficacy with 76% plaque clearance and 35% slowing in cognitive decline in early AD patients, representing another advance in disease-modifying therapy.

• Aducanumab Trial: While demonstrating dose-dependent effects on plaque clearance, this anti-amyloid therapy showed inconsistent cognitive outcomes and elevated ARIA rates, highlighting the complexity of translating amyloid reduction to clinical benefit.

• Acupuncture for Mild Cognitive Impairment (2025): A randomized, sham-controlled pilot trial with 30 participants showed no intervention-related adverse events, with both acupuncture and sham groups demonstrating clinically meaningful ADAS-cog improvements over 12 weeks, though primary outcomes did not reach statistical significance.

• Mesenchymal Stem Cell Therapy Review (2026): Analysis of 17 clinical trials demonstrated safety across different cell sources and administration routes, with Lomecel-B showing meaningful improvements in AD pathophysiology, while NEUROSTEM-AD and AstroStem failed to demonstrate statistically significant efficacy.

• A4 Study Digital Memory Assessment: This multicenter trial combining digital memory assessments with plasma pTau217 identified high-risk cognitively unimpaired adults who demonstrated the greatest cognitive decline and reached 240-week PACC decline endpoints 83 weeks earlier than the overall cohort.

Diranersen's Potential to Address Unmet Needs in Alzheimer's Treatment

Recent research highlights critical gaps in Alzheimer's disease management, with emphasis shifting toward early intervention strategies and precision medicine approaches. The field recognizes that prevention rather than cure represents the most promising therapeutic pathway, driving focus toward patients with mild cognitive impairment and early-stage disease.

Early Detection and Diagnostic Limitations:
• Current diagnostic methods remain expensive and invasive, restricting access for general populations despite the critical need for early intervention
• No single biomarker has achieved sufficient precision to replace costly PET scans and CSF assays, necessitating development of novel or combined biomarker approaches
• The lack of reliable, cost-effective screening tools particularly affects underserved populations, including Chinese-speaking communities requiring culturally accessible diagnostic instruments

Treatment Efficacy and Access Challenges:
• No definitive cure exists, with current therapies providing only symptomatic relief rather than addressing underlying pathophysiology
• Recently approved disease-modifying treatments like lecanemab and donanemab can only delay progression, not halt disease entirely
• Economic barriers persist, with lecanemab remaining non-reimbursed in markets like South Korea due to cost-effectiveness concerns and high willingness-to-pay thresholds

Target Population Focus:
• Patients with mild cognitive impairment represent the primary target population, with approximately 20 million individuals over age 55 in the EU requiring screening and potential treatment
• Cognitively normal APOE-ε4 carriers are increasingly studied as candidates for preventive interventions before cognitive decline manifests
• Advanced Alzheimer's patients remain underserved, requiring continued investment in research for treatments addressing later disease stages

Therapeutic Development Gaps:
• Multi-target therapeutic strategies are urgently needed given the multifactorial nature of neurodegeneration, moving beyond single-pathway approaches
• Effective blood-brain barrier penetration remains a significant challenge for optimal drug delivery to the central nervous system
• Patient-specific treatment prediction models are lacking, as current approaches average effects across populations without identifying optimal candidates for specific interventions

Unpacking BIIB080's Unexpected Path in Early Alzheimer's

Biogen's recent announcement regarding its Phase 2 "Celia" study of BIIB080 (diranersen) in early Alzheimer's disease presents a complex yet potentially encouraging picture for the future of AD therapeutics. While the trial notably failed its primary endpoint of demonstrating a clear dose response, the company reported "unprecedented and compelling" results, highlighting a slowing of cognitive decline across all doses, with the lowest dose showing particular efficacy. Crucially, the experimental medicine successfully reduced levels of the tau protein, a pathological hallmark of AD.

This outcome builds upon earlier Phase 1b data, which showed BIIB080, an antisense oligonucleotide (ASO) targeting the tau protein, led to dose-dependent reductions in CSF t-tau, p-tau181, and tau PET accumulation. Exploratory analyses from that study also indicated a consistent trend of slowed decline on cognitive, functional, and global measures, favoring higher-dose groups. The Phase 2 results now provide a clinical signal of cognitive benefit linked to tau reduction, addressing a key question in the literature regarding whether generalized brain tau decrease would produce positive clinical effects.

Biogen's decision to advance BIIB080 to late-stage testing underscores a strong belief in the tau pathway and the ASO modality for AD. This strategic move positions BIIB080 as a potential disease-modifying therapy, offering a distinct approach from amyloid-beta focused treatments. However, the lack of a clear dose-response in Phase 2, particularly with the lowest dose demonstrating notable efficacy, introduces a significant challenge for optimizing future trial design and could lead to complex discussions during regulatory review. Furthermore, while intrathecal administration ensures the ASO reaches the brain effectively, it remains an invasive procedure, which could impact patient acceptance and market uptake in a competitive landscape. The full data presentation at the Alzheimer’s Association International Conference in July will be critical for understanding these nuances and charting the definitive path forward for BIIB080.